Evaluation of pharmacodynamic (PD) biomarkers in patients with metastatic pancreatic cancer treated with BL-8040, a novel CXCR4 antagonist.
Manuel Hidalgo(Hospital Universitario de Fuenlabrada), Daniel D. Von Hoff(Translational Genomics Research Institute), Mitesh J. Borad(Jacksonville College), Ella Sorani, Steven M. Shaw, Joon Oh Park(Samsung Medical Center), Brian M. Wolpin(Harvard University), Ravit Geva(Tel Aviv Sourasky Medical Center), Abi Vainstein Haras, Robert A. Ramirez(Vanderbilt University Medical Center), Erkut Borazanci(HonorHealth), Amnon Peled(Hebrew University of Jerusalem), Ron Epelbaum(University of Bern), Talia Golan(Sheba Medical Center), Galia Oberkovitz, Tzipora M Lustig, Carlos Becerra(Texas Oncology), Katrina S. Pedersen(Mayo Clinic in Arizona), Valeriya Semenisty(Rambam Health Care Campus), Salomon M. Stemmer(Tel Aviv University)
Cited by 6
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k